The coronavirus disease 2019 (COVID-19) pandemic is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Based on the severity of the disease, COVID-19 is categorized as moderate, severe, and critical; most patients experience only mild symptoms and recover.Reference Deng and Peng 1 However, critically ill patients can develop acute respiratory distress syndrome (ARDS), refractory metabolic acidosis, septic shock, coagulation disorders, and multi-organ failure in a short time. Acute cardiac injury, multi-organ failure, and ARDS are serious side effects. About 26.1% of patients require ICU admission due to COVID-19 complications.Reference Huang, Wang and Li 2 Elderly people and those with underlying conditions have a poorer prognosis.Reference Deng and Peng 1 As of May 12, 2024, SARS-CoV-2 infections have resulted in 770 million confirmed cases and 7.05 million deaths worldwide. 3 Currently, available COVID-19 vaccines have been effective for the control and prevention of COVID-19 outbreaks. During this pandemic, many COVID-19 vaccines have been approved by the World Health Organization (WHO) for emergency use and are effective against SARS-CoV-2 in adults.Reference Rio, Malani and Omer 4 , Reference Mallapaty 5 Currently, six types of vaccines have been conditionally listed or approved for emergency use in China. These include two inactivated vaccines, CoronaVac and Sinopharm’s BBIBP-CorV vaccine (BBIBP-CorV), both administered in two doses; the Recombinant Novel Coronavirus vaccine (produced in CHO cells) by Zhifei Longcom, given in three doses; a single-dose Adenovirus type 5 vector vaccine by CanSino Biologics; and the two-dose mRNA vaccine, Comirnaty, developed by BioNTech and Pfizer. Among these, inactivated vaccines are traditionally used for the prevention of infectious diseases. BBIBP-CorV and CoronaVac, which are inactivated vaccines, have been proven to protect non-human primates against SARS-CoV-2Reference Gao, Bao and Mao 6. Furthermore, the safety and immunogenicity of inactivated vaccines, including BBIBP-CorV and CoronaVac, have been reported in many studies.Reference Wu, Hu and Xu 7
Sinopharm’s vaccine, also known as the BBIBP-CorV vaccine, is an inactivated vaccine candidate produced by Sinopharm’s Beijing Institute of Biological Products. Samples of the wild-type virus (HB02) are cultured in Vero cells, chemically inactivated with β-propiolactone,Reference Wang, Zhang and Huang 8 and then mixed with an aluminum-based adjuvant. This adjuvant helps to prevent infection and reinfection by stimulating the immune system to produce antibodies against SARS-CoV-2.Reference Noda, Matsuda and Yagishita 9 An interim analysis of the phase 3 study showed that the vaccine was 78.1% effective against symptomatic cases of COVID-19.Reference Al Kaabi, Zhang and Xia 10 A retrospective study of 176 640 people showed that 2 doses of the inactivated BBIBP-CorV vaccine were effective in preventing severe disease and death.Reference Ismail AlHosani, Eduardo Stanciole and Aden 11 However, in Sri Lanka, where 282 people were vaccinated with this preparation, the study showed a 10-fold reduction in neutralizing antibody titers for the Beta strain and a 1.38-fold reduction for the Delta strain compared with the reference strain.Reference Jeewandara, Aberathna and Pushpakumara 12
CoronaVac is an inactivated vaccine candidate produced by the biopharmaceutical company SinoVac (Beijing, China). Isolated SARS-CoV-2 viruses (strain CN2) were cultured in Vero cells, chemically inactivated using β-propiolactone, and mixed with an alum adjuvant.Reference Gao, Bao and Mao 6 A phase III trial in Brazil showed a vaccine efficacy (VE) of 50.7% against symptomatic COVID-19.Reference Palacios, Patiño and de Oliveira Piorelli 13 Laboratory studies have shown that serum neutralization of B.1.1.7 is less effective in recipients of this vaccine. However, the neutralizing antibody (nAb) activity against B.1.351 and P1 was significantly lower, by 5.27-fold and 3.92-fold, respectively.Reference Chen, Shen and Huang 14 , Reference Wang, Wang and Duan 15 Other data confirmed the reduced nAb activity against the P1 cell line compared to the wild-type (WT) cell line.Reference Souza, Amorim and Sesti-Costa 16 Another laboratory study demonstrated an estimated 59% VE of CoronaVac against the Delta variant.Reference Li, Huang and Wang 17
Booster vaccines enhance diminished immunity and expand the breadth of immunity against SARS-CoV-2 variants of concern. Although this study did not measure the breadth of response against variants, such assessments are crucial for a comprehensive understanding of vaccine efficacy across different viral strains. Previous studies have indicated that homologous vaccination with the BNT162b2 booster vaccine results in a significant reduction in the incidence of confirmed COVID-19 and severe disease.Reference Bar-On, Goldberg and Mandel 18 Heterologous booster strategies have also garnered significant attention, with several clinical trials and cohort studies showing that heterologous prime-boost vaccination was immunologically superior to homologous counterparts.Reference AlKaabi, Yang and Zhang 19 , Reference Wanlapakorn, Suntronwong and Phowatthanasathian 20 Boosting with either recombinant subunit, adenovirus-vectored, or mRNA vaccines after 2 doses of inactivated vaccine has been shown to improve neutralizing antibody and Spike-specific Th1-type T cell responses compared to a third dose of inactivated vaccine.Reference Zhang and He 21 , Reference Chansaenroj, Suntronwong and Kanokudom 22 For a more complete assessment, future studies should include variant-specific neutralization assays to evaluate the breadth of immune responses. The attenuation of immune response induced by 2 doses of the CoronaVac vaccine has been observed after 6 months,Reference Zeng, Wu and Pan 24 and a decrease in immunity has been noted in individuals receiving mRNA vaccines over time.Reference Pilishvili, Gierke and Fleming-Dutra 25
Matching 2 different vaccine platforms improves efficacy and elicits a strong and durable immune response.Reference Kunal, Sakthivel and Gupta 26 Heterologous primary booster vaccines against SARS-CoV-2 have been used in several countries, but there is not much evidence to support the safety and robust immunogenicity of applied heterologous regimens. We conducted this systematic study to investigate and indicate the reactogenicity and immunogenicity of heterologous vaccine regimens used to prevent COVID-19 disease (Figure 1-2). This study aimed to determine the kinetic response to antibodies in cohort participants who completed BBIBP-CorV or CoronaVac vaccinations and to explore the immunogenicity of heterologous COVID-19 booster vaccinations. These results may provide an opportunity to improve the flexibility and reliability of vaccination programs in response to the COVID-19 pandemic.
Overview of the study design and vaccination regimens used. The schematic illustrates the sequence of vaccine administration and antibody measurements.

Cartoon representation of the SARS-CoV-2 structure, highlighting key features such as the Spike protein and receptor-binding domain (RBD) that are targeted by antibodies.

Methods
Sample and Information Collection
A total of 100 subjects participated in this prospective cohort study, which took place between April 2021 and October 2021. The primary inclusion criteria were as follows: adults over 18 years old with no previous or current diagnosed infection with COVID-19 who had completed 2 doses of the Sinopharm or CoronaVac vaccine during the enrollment period with an interval of 4-6 weeks. The interval between the last vaccination and venipuncture was 2-3 weeks. In addition, participants with autoimmune diseases or cancer, those taking immunosuppressive drugs, and those who were pregnant or breastfeeding were excluded. All cases used in this study were obtained from Huaihe Hospital of Henan University. This study was approved by the Ethics Committee of Huaihe Hospital of Henan University and conducted in accordance with the Declaration of Helsinki (No. 2021165).
IgG and IgM detection
The levels of SARS-CoV-2-binding IgG and IgM antibodies were assessed using magnetic microparticle chemiluminescence immunoassay. Blood samples from 100 participants were collected, and SARS-CoV-2-specific IgG and IgM were detected using the New Coronavirus 2019-nCoV IgG/IgM Antibody Detection Kit (Chemiluminescence) from Autobio Diagnostic Co., Ltd. IgM was measured to understand its role in the anamnestic response, complementing the assessment of IgG, which is considered the primary marker for long-term protection. Future studies should prioritize measuring IgG responses to better assess protective efficacy. This product utilizes the indirect detection method. Magnetic particles are coated with 2019-nCoV antigen, and horseradish peroxidase-labeled anti-human IgG/IgM antibodies are used to prepare the enzyme conjugate. Through immunoreaction, this conjugate forms a solid-phase antigen-antibody-enzyme-labeled secondary antibody complex. The complex then catalyzes a luminescent substrate, emitting photons. The luminescence intensity is directly proportional to the concentration of IgG/IgM antibodies against the novel coronavirus (2019-nCoV). IgM detection exhibited a sensitivity and specificity of 83% and 92%, respectively, while IgG detection demonstrated a sensitivity of 87.19% and specificity of 99.69% based on premarketing clinical evaluations. Antibody levels were expressed as the measured chemiluminescence value divided by the cutoff value (S/Co).Reference Du, Cao and Zhu 27
ELISA Quantification
Specific vaccine-induced IgG responses to the SARS-CoV-2 Spike protein were quantified using an ELISA kit (Sino Biological Inc., China, KIT40592) following the manufacturer’s protocol. Well strips pre-coated with SARS-CoV-2 Spike protein were used. Standards and specimens (100 μL) were dispensed into appropriate wells and incubated at 37°C for 30 minutes. Following incubation, 100 μL of diluted HRP-conjugated anti-Spike antibodies were added to each well and incubated at room temperature (RT) for 1 hour. After washing with the washing buffer, 100 μL of TMB substrate solution and 100 μL of stabilized hydrogen peroxide were added to each well and incubated at RT in the dark for 30 minutes. The reaction was stopped by adding 50 μL of 2 N sulfuric acid, and the absorbance was read at 450 nm using a microtiter well reader.
Statistical Analysis
Participant demographics were summarized using descriptive statistics. Continuous data were presented as mean ± standard error (SE), median (lower quartile, upper quartile), and range. Statistical analyses were conducted using GraphPad Prism 8. Continuous variables were analyzed using one-way ANOVA or the Kruskal-Wallis test, as appropriate. A P value less than 0.05 was considered statistically significant.
Results
Demographic Features
A total of 100 participants were included in this study. Participants received the first and second doses of the vaccine 4-6 weeks apart, and the interval between the last vaccination and venipuncture was 2-3 weeks. The mean age of the participants was 38 years (range 18-59). Among them, there were 47 males (47%) with a median age of 36 years and a mean age of 39 years. There were 53 females (53%) with a median age of 35 years and a mean age of 38 years. Twenty-five participants received 2 doses of CoronaVac, 25 participants received a heterologous BBIBP-CorV booster, 25 participants received 2 doses of BBIBP-CorV, and 25 participants opted for a heterologous boost with CoronaVac after initially receiving 1 dose of BBIBP-CorV vaccine (Table 1).
Demographic information of participants enrolled

The level of specific IgG antibodies against SARS-CoV-2
To assess the impact of different vaccines, IgG antibody levels against SARS-CoV-2 were analyzed in the aforementioned 4 participant groups. As depicted in Figure 3A, the mean S/CO value of IgG antibodies in the heterologous CoronaVac boost group was 11.75 ± 2.88, significantly higher than the 9.64 ± 2.88 observed in the homologous BBIBP-CorV boost group (P < 0.05). Conversely, the mean S/CO value in individuals who received a homologous CoronaVac boost was 5.28 ± 0.45, whereas it increased to 9.64 ± 2.28 in the heterologous BBIBP-CorV boost group (P < 0.05).
(A) Average concentration of SARS-CoV-2 IgG antibodies induced by 4 types of vaccinations. (B) Comparison of SARS-CoV-2 IgM antibody levels induced by 4 types of vaccinations. (C) Average concentration of SARS-CoV-2 Spike antibody induced by 4 types of vaccinations. The data show significant differences in antibody levels between the different vaccination regimens. *p < 0.05, ****p < 0.0001.

The level of specific IgM antibodies against SARS-CoV-2
The level of specific IgM antibodies against SARS-CoV-2 was measured to complement our assessment of IgG responses. As shown in Figure 3B, the IgM antibody level in the heterologous CoronaVac boost group was 0.82 ± 0.20, significantly higher than that in the homologous BBIBP-CorV boost group (0.56 ± 0.16, P < 0.05). This trend continued with the heterologous BBIBP-CorV boost group (mean = 0.30 ± 0.08), which exhibited higher levels compared to the homologous CoronaVac boost group (mean = 0.18 ± 0.04). While IgM provides early immune response insights, IgG remains a critical marker for assessing long-term protection. Future studies should focus on IgG responses for a clearer understanding of protective efficacy.
Spike antibody response against SARS-CoV-2
By day 28, spike antibody in the heterologous CoronaVac boost group (200.30 ± 80.04 pg/mL) was significantly higher than the homologous BBIBP-CorV boost group (127.50 ± 63.64 pg/mL, P < 0.0001), and the spike antibody in the heterologous BBIBP-CorV boost group (53.93 ± 34.39 pg/mL) was significantly higher than homologous CoronaVac boost group (9.60 ± 4.53 pg/mL, P < 0.05) (Figure 3C).
Gender differences in Spike protein levels
We also evaluated the spike antibody levels between male and female participants. For participants who received one dose of vaccine followed by a heterologous CoronaVac or BBIBP-CorV boost, the SARS-CoV-2 IgG antibody levels were higher in female participants compared to male participants (Figure 4 A-D).
(A-D) Comparison of SARS-CoV-2 IgG antibody concentrations between male and female participants across different vaccination groups. (E) Average concentrations of SARS-CoV-2 IgG antibodies in different age groups. The data illustrate variations in immune responses by sex and age, with statistical comparisons between groups. *p < 0.05.

Effect of age on antibody production
Participants were categorized into 2 age groups: 18-39 years (71%) and 40-59 years (29%). As illustrated in Figure 4, the mean spike antibody titer in the older age group (87.53 ± 64.68) was lower than that in the younger group (199.90 ± 98.61, P < 0.05) (Figure 4E).
Discussion
Vaccination is critical in triggering immune responses for disease prevention, particularly against rapidly spreading viruses like SARS-CoV-2. Following infection, individuals typically develop neutralizing antibodies against SARS-CoV-2, although these antibodies wane over time.Reference Legros, Denolly and Vogrig 28 Reports indicate that memory B cell responses and Spike-specific CD4+ T cell responses diminish over time.Reference Israel, Shenhar and Green 29 Gaebler et al. observed significant declines in anti-RBD and anti-N antibodies in plasma between 1.3-6.2 months post-infection, alongside reductions in IgM and IgG titers against the Spike protein’s receptor-binding domain.Reference Wheatley, Juno and Wang 30
In our study, we evaluated the efficacy of 2 vaccine platforms in inducing antibodies against SARS-CoV-2. T cells play a crucial role in instructing B cells to proliferate, switch their antigen receptor classes, form germinal centers, and differentiate into plasma blasts—the initial antibody-secreting cells.Reference Quast and Tarlinton 31 IgM antibodies, indicative of early infection, typically appear 5-8 days post-viral exposure and have a relatively short lifespan. In contrast, IgG antibodies, which appear later, provide prolonged protection by preventing viral entry into cells.Reference Zhao, Zhao and Ou 32 Consistent with previous studies by Fan et al., our findings indicated significantly higher IgG levels compared to IgM, underscoring the durability of IgG responses.Reference Shuangyan, Lin and Cheng 33 IgM’s short half-life contrasts with IgG’s persistence of approximately 3-4 weeks.Reference Baumgarth, Nikolich-Zugich and Lee 34 aligning with our observed higher IgG levels.
Recent studies suggest that combining different vaccine types, such as administering an mRNA booster following ChAdOx1 nCoV-19 (Oxford-AstraZeneca), can enhance neutralizing antibody levels.Reference Normark, Vikstrom and Gwon 35 Boosting with recombinant protein subunit vaccine ZF2001 after 2 doses of inactivated vaccines (CoronaVac or BBIBP-CorV) also significantly improved anti-RBD responses and neutralizing titers against SARS-CoV-2 variants.Reference Ai, Zhang and Zhang 36 Heterologous boosting strategies, involving recombinant subunit, adenovirus-vectored, or mRNA vaccines after 2 doses of inactivated vaccines, notably enhanced neutralizing antibody and Spike-specific Th1-type T cell responses compared to a third dose of inactivated vaccine alone.Reference Aksoyalp and Nemutlu-Samur 37 In our investigation, participants receiving heterologous vaccines showed markedly higher spike antibody levels than those receiving homologous booster vaccines.
Current data on sex-specific responses to COVID-19 vaccines are limited, complicating comprehensive conclusions regarding sex differences in vaccine efficacy and safety.Reference Aksoyalp and Nemutlu-Samur 37 Sex-related disparities in innate and adaptive immune responses, X-linked gene expression, ACE2 receptor expression, sex hormone levels, and microbiome composition may contribute to differential vaccine responses.Reference Flanagan, Fink and Plebanski 38 Notably, females tend to exhibit higher immunoreactivity post-vaccination for diseases like hepatitis, yellow fever, and influenza compared to males.Reference Klein, Marriott and Fish 39 Additionally, women may experience more frequent and severe adverse reactions and are predisposed to autoimmune and allergic responses more than men.Reference McNeil, Weintraub and Duffy 40 Following BNT162b2 vaccination, females demonstrated significantly higher anti-SARS-CoV-2 IgG levels than males.Reference Pellini, Venuti and Pimpinelli 41 In our study, although females exhibited higher antibody titers than males, statistical significance was not achieved due to the study’s small sample size.
Aging induces various immune system alterations, including reduced responsiveness to novel antigens, diminished T cell memory recall, and chronic inflammation. Elderly individuals exhibit lower somatic hypermutation in class-switched cells.Reference Müller, Andrée and Moskorz 42 Spike-specific T cells in older participants produce less interferon and interleukin-2, with CD4 T cells being the primary source of these cytokines. This diminished immune responsiveness in the elderly correlates with higher rates of infection-related morbidity and poorer vaccine responses due to declining cellular and humoral immunity.Reference Pera, Campos and López 43 Studies have consistently reported lower anti-Spike IgG concentrations in individuals aged 80 years or older compared to younger age groups.Reference Collier, Ferreira and Kotagiri 44 In our study, antibody levels were significantly higher in the 18-39 age group compared to older participants.
Limitations
This study has several limitations. Firstly, the cohort size was relatively small, limiting the generalizability of findings from Huaihe Hospital of Henan University. Secondly, the single blood sample per participant prevented longitudinal tracking of individual antibodies and Spike antibody levels over time, hindering dynamic assessment. Future studies with larger, diverse cohorts receiving various vaccines are essential to elucidate vaccine-specific outcomes and the role of SARS-CoV-2 antibody in COVID-19 prevention.
Conclusions
In conclusion, our study assessed SARS-CoV-2 IgG, IgM antibodies, and Spike antibody levels in 100 participants, comparing protective antibody titers following homologous and heterologous second-dose vaccinations. Booster immunization is currently recommended in China, with attention warranted for individuals exhibiting low antibody levels to potentially necessitate booster doses for enhanced protection.
Data availability statement
The datasets during the current study are available from the corresponding author on reasonable request.
Acknowledgments
The authors express their gratitude to all participants who contributed to this research.
Funding statement
This work was supported in part by grants from the National Natural Science Foundation of China (81500430, U1304802), the Science and Technology Planning Project of Henan Province (192102310045) awarded to Xuhong Lin, and the Medical Science and Technology Project of Henan Province (2018020320) awarded to Huichao Wang.
Competing interest
The authors declare no competing interests.
Ethical standard
This study was approved by the Ethics Committee of Huaihe Hospital of Henan University, where the work was conducted, and adhered to the principles outlined in the Declaration of Helsinki. The reference number for the ethics approval is 2021165.

